HEHans Eiskjær

Hans Eiskjær

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hans Eiskjær has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Efficacy of Implantable Cardioverter Defibrillator in Nonischemic Systolic Heart Failure According to Sex: Extended Follow-Up Study of the DANISH Trial

    by Jawad H. Butt, Adelina Yafasova, Marie B. Elming, Ulrik Dixen, Jens C. Nielsen, Jens Haarbo, Lars Videbæk, Eva Korup, Niels E. Bruun, Hans Eiskjær, et al.

    Background: Men and women may respond differently to certain therapies for heart failure with reduced ejection fraction, including implantable cardioverter defibrillators (ICD). In an extended follow-up study of the DANISH trial (Danish Study to Assess the Efficacy of ICDs in Patients With Non-Ischemic Systolic Heart Failure on Mortality), adding 4 years of additional follow-up, we examined the effect of ICD implantation according to sex. Methods: In the DANISH trial, 1116 patients with nonischemic systolic heart failure were randomized to receive an ICD (N=556) or usual clinical care (N=550). The primary outcome was all-cause mortality. Results: Of the 1116 patients randomized in the DANISH trial, 307 (27.5%) were women. During a median follow-up of 9.5 years, women had a lower associated rate of all-cause mortality (hazard ratio [HR], 0.60 [95% CI, 0.47–0.78]) cardiovascular death (HR, 0.62 [95% CI, 0.46–0.84]), nonsudden cardiovascular death (HR, 0.59 [95% CI, 0.42–0.85]), and a numerically lower rate of sudden cardiovascular death (HR, 0.70 [95% CI, 0.40–1.25]), compared with men. Compared with usual clinical care, ICD implantation did not reduce the rate of all-cause mortality, irrespective of sex (men, HR, 0.85 [95% CI, 0.69–1.06]; women, HR, 0.98 [95% CI, 0.64–1.50]; Pinteraction=0.51). In addition, sex did not modify the effect of ICD implantation on sudden cardiovascular death (men, HR, 0.57 [95% CI, 0.36–0.92]; women, HR, 0.68 [95% CI, 0.26–1.77]; Pinteraction=0.76). Conclusions: In patients with nonischemic systolic heart failure, ICD implantation did not provide an overall survival benefit, but reduced sudden cardiovascular death, irrespective of sex. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00542945.


  • Burden of arrhythmia and silent ischemia in heart transplant patients with cardiac allograft vasculopathy

    by Katrine Berg, Kamillla Pernille Bjerre, Tor Skibsted Clemmensen, Brian Bridal Løgstrup, Henning Mølgaard, Steen Hvitfeldt Poulsen, Hans Eiskjær

    The incidence of sudden cardiac death (SCD) following heart transplantation (HTx) accounts for approximately 10% of post-HTx deaths. Ischemia, brady- and tachy-arrhythmias caused by rejection and cardiac allograft vasculopathy (CAV) seem related to SCD. Hence, we aimed to investigate the relation between CAV, arrhythmias and silent ischemia in long-term HTx patients. Methods. 49 HTx patients were included. Patients were CAV classified in accordance with guidelines from the International Society of Heart and Lung Transplantation. Patients were divided into predefined CAV groups (CAV 0, CAV 1, CAV 2 + 3). Incidences of arrhythmia and silent ischemia were detected by 48-h electrocardiogram monitoring and analyzed blinded to CAV-status. Results. Median time since transplantation was 9 years [IQR 4–14]. We observed a higher incidence of non-sustained ventricular tachycardia (NSVT) in CAV 2 + 3 patients than CAV 0 and 1 patients (p = .01). Likewise, isolated premature ventricular complexes (PVC) (p = .01) and PQ-interval prolongation (p = .01) were more frequent in CAV 2 + 3 patients than CAV 0 and 1 patients. Silent ischemia was only observed among CAV 3 patients (p = .04). We saw no significant difference in the incidence of supraventricular tachycardia among CAV groups (p = .21). Likewise, no difference in the right bundle branch block was observed (p = .68). Conclusion. NSVT was associated with CAV status in long-term HTx patients. Patients with moderate to severe CAV showed higher incidences of PVCs and PQ-interval prolongation than patients with mild or no CAV. Silent ischemia was only seen in patients with severe CAV.


    • 1 October 2018
      • Vol. 180

    [Treatment of heart failure in patients with reduced left- ventricular ejection fraction].

    by Hans Elskjær

    Treatment of heart failure with reduced ejection fraction has undergone an enormous development over the latest three decades resulting in lower mortality. Standard treatment now includes use of angiotensin-converting-enzyme (ACE)-inhibitors, beta blockers and mineralocorticoid receptor antagonists. Diuretics are still the cornerstone in the symptomatic treatment of fluid retention. Combined angiotensin II receptor blockade and neprilysin inhibition is a new treatment option instead of ACE-inhibition for selected patients. Cardiac resynchronisation therapy and prophylactic implantable cardiac defibrillators further reduce mortality.